Huperzine A at a glance
Huperzine A is an alkaloid from the club moss Huperzia serrata. It blocks acetylcholinesterase, the enzyme that breaks down the messenger acetylcholine. In a 2013 review of 20 trials in Alzheimer’s disease, all but one were run in China. The one trial we found in trained adults showed no change in cognition or exercise performance. China licenses huperzine A as a medicine, while food authorities in several EU countries have reported it in supplements as an unauthorised novel food.
Evidence: Human trials, mostly in Alzheimer’s disease · Updated 20 November 2026
What huperzine A is
Huperzine A is an alkaloid isolated from Huperzia serrata, a club moss used in Chinese folk medicine under the name Qian Ceng Ta. Researchers in China identified it as an acetylcholinesterase inhibitor in the 1980s. A 2014 review describes it as a licensed medicine for Alzheimer’s disease in China and a dietary supplement in the US.
Hammer Labz panels list either huperzine A or an extract of the plant standardised to a share of huperzine A. The difference matters for the amounts below.
How it works
Acetylcholinesterase is the enzyme that breaks down acetylcholine, a chemical messenger of the nervous system. Huperzine A is a potent, highly specific and reversible inhibitor of this enzyme: it blocks it for a time and then lets go.
A 2006 review from the Shanghai Institute of Materia Medica compared it with the dementia medicines tacrine, donepezil and rivastigmine. By that account, huperzine A passes into the brain more easily, is absorbed better by mouth and acts for longer.
In a US Army study of healthy adults, single doses of 100 or 200 mcg lowered acetylcholinesterase activity in the blood. A related enzyme, butyrylcholinesterase, did not change. For the supply side of the same system, see our alpha-GPC card.
Evidence
Evidence label: Human trials, mostly in Alzheimer’s disease. Our labels describe the ingredient, not a product; see how we review.
Alzheimer’s disease. A 2013 meta-analysis pooled 20 randomised trials with 1,823 people with Alzheimer’s disease. All but one were run in China, and most had a high risk of bias. Against placebo, huperzine A improved scores on the Mini-Mental State Examination at 8, 12 and 16 weeks. The authors advise caution because of the trials’ poor methods.
The one trial in that analysis run outside China was a US phase II trial in 210 people with mild to moderate Alzheimer’s disease. At 200 mcg twice a day, huperzine A did not change the main cognitive score at 16 weeks. At 400 mcg twice a day, a secondary analysis found a gain at 11 weeks that was no longer statistically significant at 16 weeks.
Healthy people. In 15 exercise-trained adults, 11 of them women, a single 200 mcg dose did not change cognitive tests compared with placebo. Balance, dart throwing, estimated aerobic capacity, grip strength, jump height and push-ups did not change either. After exercise, they rated the session as harder with huperzine A: 6.8 against 5.7 on a 0–10 scale. This is the only exercise trial of huperzine A we found (PubMed search, 20 November 2026).
In the US Army study, the 200 mcg dose kept recall steady across test sessions, while other tests did not improve.
Use with care. In the 2013 meta-analysis, side effects were mild. Nausea, loss of appetite, dizziness and vomiting were reported most often, and two trials reported a slow heart rate. No trial reported a severe adverse event.
Huperzine A blocks the same enzyme as the dementia medicine donepezil. The US label of donepezil warns that medicines of this class can interfere with anticholinergic drugs. They can also add to the effect of cholinergic drugs and of some muscle relaxants used in anaesthesia. Check with a doctor before using a product with huperzine A if you take any medication, have a heart condition or asthma, or have surgery planned.
Amounts on labels
| Hammer Labz product | As written on the label | Label serving |
|---|---|---|
| Lion Blood | Huperzine A 250 mcg | 1 cap (20 ml) |
| Oxy-Dren | Huperzine A 250 mcg | as listed on the panel |
| Lipo Shred | Huperzia serrata (aerial) (≥1% huperzine A) 300 mcg | 2 capsules |
| Atomic Strength | Huperzine A 1% 100 mcg | 1 scoop (10 g) |
Lipo Shred’s 300 mcg is the weight of the extract, not of huperzine A, and Atomic Strength’s label leaves open whether its 100 mcg is extract or huperzine A.
The Alzheimer’s trials in the 2013 meta-analysis used 200 to 800 mcg of huperzine A a day for 8 to 36 weeks. The trial in trained adults used a single 200 mcg dose.
Legal and anti-doping status
Status checked on 20 November 2026.
- EU, food: the EU novel food catalogue has no entry for huperzine A or Huperzia serrata, which does not settle their status. Neither is on the Union list of authorised novel foods. Food authorities in Sweden, Poland, Germany, France and other EU countries have reported huperzine A or Huperzia serrata extract in supplements as an unauthorised novel food. Their notifications in RASFF, the EU’s rapid alert system, date from 2021 to October 2026.
- EU, medicines: we found no medicine containing huperzine A in the European Medicines Agency’s database of medicines authorised in the EU and EEA, searched under the compound and plant names.
- WADA: huperzine A is not named on the 2026 or 2027 WADA List. If you are a tested athlete, check any supplement with your anti-doping organisation.
- Not for drug-tested athletes: Lion Blood, Lipo Shred and Atomic Strength list DMHA, and Atomic Strength and Oxy-Dren list DMAA. Oxy-Dren also lists ephedra, Atomic Strength lists octopamine and methylsynephrine, and Lipo Shred lists higenamine. WADA names DMAA, ephedrine, octopamine, oxilofrine (methylsynephrine) and octodrine, one of two compounds sold as DMHA, in class S6, prohibited in competition. Higenamine is in class S3, prohibited at all times. Oxy-Dren also lists two forms of yohimbine; see our yohimbine card.
Status differs by country and changes over time.
Found in
Hammer Labz (brand page)
- Lion Blood
- Oxy-Dren
- Lipo Shred (as Huperzia serrata extract)
- Atomic Strength
Haya Labs
- Haya Huperzine A 98% 200 mcg (90 capsules)
We have not seen the Haya Labs label, so we give no amount.
Sources
- Product labels: Hammer Labz supplement facts panels for Lion Blood, Oxy-Dren, Lipo Shred and Atomic Strength, as listed in November 2026.
- Desilets AR, Gickas JJ, Dunican KC (2009). Role of huperzine a in the treatment of Alzheimer’s disease. Ann Pharmacother, 43(3), 514–518. PMID: 19240260.
- Qian ZM, Ke Y (2014). Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer’s Disease? Front Aging Neurosci, 6, 216. PMID: 25191267.
- Yang G, Wang Y, Tian J, et al. (2013). Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One, 8(9), e74916. PMID: 24086396.
- Wang R, Yan H, Tang XC (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin, 27(1), 1–26. PMID: 16364207.
- Morasch KC, Aaron CL, Moon JE, et al. (2015). Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults. Physiol Behav, 138, 165–172. PMID: 25455867.
- Rafii MS, Walsh S, Little JT, et al. (2011). A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology, 76(16), 1389–1394. PMID: 21502597.
- Wessinger CM, Inman CL, Weinstock J, et al. (2021). Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial. Int J Exerc Sci, 14(2), 727–741. PMID: 34567353.
- Eisai Inc. Aricept (donepezil hydrochloride): US prescribing information. DailyMed, National Library of Medicine. Label revised December 2021. Accessed 20 November 2026.
- European Commission. EU Novel Food status catalogue. Searched for huperzine A and Huperzia serrata. Accessed 20 November 2026.
- European Union. Commission Implementing Regulation (EU) 2017/2470 establishing the Union list of novel foods. Consolidated text of 10 August 2026. Accessed 20 November 2026.
- European Commission. RASFF Window: Rapid Alert System for Food and Feed. Notifications on huperzine A and Huperzia serrata in food supplements, 2021–2026. Accessed 20 November 2026.
- European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 20 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 16 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 16 November 2026.
